PGDx has developed a portfolio of standardized tissue-based and liquid biopsy next-generation sequencing (NGS) assays for laboratories worldwide, featuring automated bioinformatics that ensures consistent results and quality of testing. By automating the data analysis process, PGDx is enabling the scalability of precision medicine with a fast, reliable, and accurate system.

Our portfolio of NGS assays works in all solid tumors to identify clinically actionable and guideline supported biomarkers to inform treatment decisions for patients with advanced cancer. With an in-house testing option, PGDx is empowering healthcare professionals to more rapidly identify patients’ unique biomarkers and inform care pathways that optimize treatment options for patients.

The PGDx elio™ Advantage

  • Ability to utilize local laboratory and pathologist expertise

  • Avoid send out testing

  • Maintain ownership of valuable samples, data, and patient results

  • Deliver actionable results in as little as 4-5 days

  • Manage testing schedule and lab priorities

  • Faster turnaround time to reliable results, enabling the best and most informed treatment decisions

PGDx elio™: Empowering Local Insight for Oncology

          INTUITIVE USER INTERFACE
SYSTEM QUALITY
CONTROL SOFTWARE
  AUTOMATED PIPELINES
 DEVELOPED WITH ARTIFICIAL INTELLIGENCE
ASSAY PIPELINES

Platform Metrics

4-7 Days Turn-Around Time
Sample Types Tissue & Liquid Biopsy
Automated Analysis Bioinformatics